Q-omics provides the consensus-scored ZNF229 profile across patient tissues and cancer cell-line models. ZNF229 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ZNF229 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, ZNF229 RNA expression shows 18,564 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where ZNF229 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF229 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF229 survival associations across molecular data types. ZNF229 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF229 RNA expression–survival associations across cancer types. High ZNF229 expression shows unfavorable associations in STAD and MESO, but favorable associations in UVM, OV, KIRP and SCLC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify STAD as the clearest survival context for ZNF229 RNA expression.
This table summarizes ZNF229 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF229. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF229 shows lower tumor expression in KIRC, COAD, HNSC, THCA and KICH and higher tumor expression in LUAD. The KIRC box plot shows higher ZNF229 RNA expression in normal versus tumor tissue (log2 FC = −0.663, t-test p < 0.001).
This table shows molecular features associated with ZNF229 in patient tissues and cancer cell lines. In patient samples, ZNF229 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF229 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
